{"disease":{"id":"glioblastoma","name":"Glioblastoma","therapeutic_area":"Oncology","data":{"aiSummary":"The treatment landscape for glioblastoma involves a multimodal approach, with surgery, radiation, and temozolomide being the standard of care. Bevacizumab is sometimes used in recurrent disease. Recent advances include the development of targeted therapies and immunotherapies, though these are still largely in clinical trials. The pipeline includes agents targeting various pathways, such as EGFR, and immune checkpoints, with the goal of improving patient outcomes and survival.","drug_count":5,"description":"Glioblastoma (GBM) is a highly aggressive brain cancer characterized by rapid growth and infiltration into surrounding brain tissue. It arises from glial cells and is associated with a poor prognosis due to its resistance to treatment and high recurrence rate. Current treatment strategies involve a combination of surgery, radiation therapy, and chemotherapy.","subtype_count":9},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.928Z","updated_at":"2026-03-25T12:16:34.928Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bevacizumab","indication_name":"Glioblastoma multiforme","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avastin","generic_name":"bevacizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":82,"revenue":"2100","mechanism":"Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic glioblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"avastin","indication_name":"Glioblastoma multiforme","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avastin","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"carmustine","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gliadel","generic_name":"CARMUSTINE","company_name":"Avet Lifesciences","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"Alkylating Drug","quality_score":69,"revenue":null,"mechanism":"Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"zirabev","indication_name":"Glioblastoma multiforme","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab","generic_name":"Bevacizumab-Bvzr","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular Endothelial Growth Factor (VEGF)","drug_class":"Monoclonal antibody","quality_score":74,"revenue":null,"mechanism":"Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR."},{"drug_id":"temodal","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Temodal","company_name":"Armando Santoro, MD","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":3,"revenue":null,"mechanism":null},{"drug_id":"carmustin","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carmustin","company_name":"University Hospital Freiburg","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"temozolomide","indication_name":"Glioblastoma multiforme of brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temodar","generic_name":"temozolomide","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Temodar works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"bevacizumab-maly","indication_name":"Recurrent Glioblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"phytonadione","indication_name":"Glioblastoma","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":9,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06717295","title":"The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Javier Toledo","has_results":false},{"nct_id":"NCT00009035","title":"Natural History of Patients With Brain and Spinal Cord Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":3050,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06160596","title":"Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis","phase":"","overall_status":"RECRUITING","enrollment_count":1020,"lead_sponsor_name":"Cure 51","has_results":false},{"nct_id":"NCT06146738","title":"The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)","phase":"","overall_status":"RECRUITING","enrollment_count":1015,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT07448480","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT04471844","title":"Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM","phase":"NA","overall_status":"COMPLETED","enrollment_count":981,"lead_sponsor_name":"NovoCure Ltd.","has_results":false},{"nct_id":"NCT00943826","title":"A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":921,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06118723","title":"The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)","phase":"","overall_status":"RECRUITING","enrollment_count":784,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT03345095","title":"A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":749,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":true},{"nct_id":"NCT03722355","title":"Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Radiation Therapy Oncology Group","has_results":false},{"nct_id":"NCT02573324","title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":691,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT00031538","title":"Genetic Analysis of Brain Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":674,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00884741","title":"Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":637,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02179086","title":"Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":606,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT04427384","title":"Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"GT Medical Technologies, Inc.","has_results":false},{"nct_id":"NCT06041555","title":"MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03770468","title":"Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma","phase":"","overall_status":"COMPLETED","enrollment_count":599,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT06146725","title":"The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)","phase":"","overall_status":"RECRUITING","enrollment_count":564,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT05902169","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":560,"lead_sponsor_name":"CarThera","has_results":false},{"nct_id":"NCT06477939","title":"Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":554,"lead_sponsor_name":"Institut de cancérologie Strasbourg Europe","has_results":false},{"nct_id":"NCT02017717","title":"A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":529,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04359745","title":"Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT05099068","title":"Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT04717739","title":"TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"NovoCure Ltd.","has_results":false},{"nct_id":"NCT05624736","title":"Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT06283927","title":"The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)","phase":"","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT02977780","title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Patrick Wen, MD","has_results":false},{"nct_id":"NCT04708171","title":"The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections","phase":"","overall_status":"RECRUITING","enrollment_count":453,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT02152982","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":447,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05271240","title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT06924099","title":"TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)","phase":"","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"NovoCure Ltd.","has_results":false},{"nct_id":"NCT03975959","title":"Memory Perception Assessment in Central/Non-central Nervous System Cancers","phase":"NA","overall_status":"COMPLETED","enrollment_count":426,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT06740955","title":"Hypofractionated Radiotherapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT03787056","title":"Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02414165","title":"The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":403,"lead_sponsor_name":"Tocagen Inc.","has_results":false},{"nct_id":"NCT06348693","title":"Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","has_results":false},{"nct_id":"NCT07452458","title":"Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":398,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT04536649","title":"Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":369,"lead_sponsor_name":"Shanghai Proton and Heavy Ion Center","has_results":false},{"nct_id":"NCT05839379","title":"Targeted Pediatric High-Grade Glioma Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT05370079","title":"Control Cohort CTRL COH","phase":"NA","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04752280","title":"Glioblastoma Radiotherapy Using IMRT or Proton Beams","phase":"NA","overall_status":"RECRUITING","enrollment_count":326,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT05641220","title":"Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":325,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT02327078","title":"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03439332","title":"Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma","phase":"","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"Juan M Garcia-Gomez","has_results":false},{"nct_id":"NCT05934630","title":"Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors","phase":"","overall_status":"SUSPENDED","enrollment_count":300,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}